✦ LIBER ✦

6510 ORAL Erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): interim results from the European subpopulation of the open-label TRUST study

✍ Scribed by Smit, E.; Reck, M.; Krzakowski, M.; Gridelli, C.; Curescu, S.; Berzinec, P.; Barata, F.; McDermott, R.; Jovanovic, D.; Magyar, P.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of erlotinib in patients with a

✍ Michael BOYER; Keith HORWOOD; Nick PAVLAKIS; Paul DE SOUZA; Michael MILLWARD; Br 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Second-line erlotinib in patients with a

✍ Heigener, David F.; Wu, Yi-Long; van Zandwijk, Nico; Mali, Pekka; Horwood, Keith 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 347 KB

9165 Motesanib or bevacizumab in combina

✍ Blumenschein, G.; Schwartzberg, L.S.; Menon, H.; Mok, T.S.K.; Stephenson, J.J.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Survival outcomes in patients with advan

✍ Van Meerbeeck, J.; Galdermans, D.; Bustin, F.; De Vos, L.; Lechat, I.; Abraham, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 551 KB

A prospective, phase II, open-label stud

✍ Goto, Koichi; Nishio, Makoto; Yamamoto, Noboru; Chikamori, Kenichi; Hida, Toyoak 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 948 KB

9006 Safety of bevacizumab (BV) combined

✍ Jahanzeb, M.; Fischbach, N.; Kosty, M.; Kumar, P.; Spigel, D.; Wozniak, A.; Teng 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB